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Abstract 
 
The application of unit resolution tandem quadrupole and high-resolution orthogonal-
acceleration time-of flight mass spectrometers for the quantitation and translational 
analysis of proteolytic peptides is described. The mass spectrometry platforms were 
contrasted in terms of sensitivity and linear response. Moreover, the selectivity of the 
platforms was investigated and the effect on quantitative precision studied. 
Chromatographic LC conditions, including gradient length and configuration, were 
investigated with respect to speed/throughput, whilst minimizing isobaric interferences, 
thereby providing information with regard to practical sample cohort size limitations of 
LC-MS for large cohort experiments. In addition to these fundamental analytical 
performance metrics, precision and linear dynamic range were also studied. An LC-MS 
configuration that encompasses the best combination of throughput and analytical 
accuracy for translational studies was chosen, despite the MS platforms giving similar 
quantitative performance, and instances were identified where alternative combinations 
were found to be beneficial. This configuration was utilized to demonstrate that 
proteolytically digested non-depleted samples from heart failure patients could be 
classified with good discriminative power using a subset of proteins previously suggested 
as candidate biomarkers for cardiovascular diseases. 
 
 
Significance of the study 
 
The understanding of disease and drug development is critical in both discovery and 
translational clinical studies. The differentiation and validation of the integral biological 
components are however technologically challenging. The results from this study 
demonstrate clear technological advances that will assist and accelerate validation of 
early phase discoveries. 
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Introduction 
 
Bioanalytical proteomics workflows originally consisted of the qualitative profiling of two 
or more samples/groups using gel-based separation techniques with some type of optical 
read-out [1,2]. The benefits of mass spectrometry were readily recognised with the 
development of in-gel digestion and peptide extraction techniques in combination with 
peptide mass fingerprint MALDI time-of-flight [3] and nanoelectrospray tandem mass 
spectrometry [4] making protein identification more routine and main stream. The 
following advances included the use of one and two-dimensional nanoscale LC 
chromatography, originally developed by the chromatographic community but embraced 
and brought forward by the proteomics community because of increased method 
sensitivity, which afforded the analysis of more complex samples in an automated 
fashion. Meanwhile, continued high-resolution mass spectrometer developments, such as 
modes of acquisition, resolution, analyzer types and combinations, speed and sensitivity, 
lead to the identification of more proteins and putative disease markers at increasingly 
faster identification rates. The more recent developments include the incorporation of 
orthogonal separation techniques within instruments designs, as for example, ionic gas 
phase based ion-mobility [5,6]. 
Quantitation in discovery LC-MS based proteomics experiments is typically conducted 
by either labelled or label-free methods. Labels can be incorporated metabolically or by 
using chemical techniques [7,8]. In both instances, a known or predictable peptide mass 
shift is introduced, affording the differential quantitation of peptides and their parent 
proteins. The read-out can be either at the precursor, including techniques such as ICAT, 
SILAC, dimethyl-labelling [9-11], or at the product ion level, of which iTRAQ and TMT 
labelling are representatives [12,13]. The former methods limit the experimental design 
in terms of the number of samples that can be compared, but arguably provide the best 
precision, whereas the latter methods provide a higher degree of multiplexing but at the 
cost of reduced dynamic quantitation range. Label-free methods have gained great 
popularity over the last decade with ion abundance based methods believed to provide 
the best accuracy and precision [14-16]. Appealing benefits of these methods are the 
increased dynamic range and the freedom in experimental design compared to 
quantitative labelled LC-MS methods. An additional benefit is that the amount of the 
identified proteins can be estimated without the use of stable isotope labelled standards 
[17]. Attention has to be given however to experimental variation as this is carried 
through and affects the total observed error. 
Targeted LC-MS based assays are increasingly applied in the post-discovery 
proteomics area with emphasis on validation, the first of many phases in translational 
analyses, or in studies that are aimed at gaining the understanding of biological systems, 
drug development and treatment. Context is driving current proteomics experiments, 
thereby also driving the development of LC-MS acquisition methods that can provide 
both qualitative and quantitative information in a single experiment. With the increased 
availability of spectral libraries and public discovery results repositories [18,19], the 
identification of disease related or pathway associated proteins is not seen, or at least 
strongly reduced, as a prerequisite for larger scale, confirmatory type studies. Moreover, 
targeted, multiplexed assays are believed to be a viable alternative for antibody based 
assays because of improved specificity. Both tandem quadrupole and high-resolution 
mass spectrometers are applied for these types of studies [20-23]. Multiple/selected 
reaction monitoring (MRM/SRM) based assays are especially believed to have the 
potential to afford protein quantitation with the reproducibility and throughput required 
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in order to improve biomarker acceptance. These types of experiments are however 
technologically challenged since they require analyzing a large number of samples with 
high-throughput, but also require high sensitivity, high resolution, large dynamic range 
and excellent selectivity at the same time. Here, tandem quadrupole and high-resolution 
mass spectrometers are systematically compared to demonstrate and contrast the 
application of these analyzer types and how they could be operated for targeted protein 
quantitation experiments. In addition, two different types of LC interfaces have been 
evaluated with regard to their contribution to throughput/robustness vs. sensitivity. A 
small cohort of heart failure disease patient blood samples was analyzed. Heart failure 
(HF) poses a significant burden on healthcare systems around the world. The causes of 
HF are disparate and can involve interplay between several biological systems [24]. An 
examination of the expression of thirteen proteins that populate biological pathways 
intertwined with HF will test the feasibility and potential use of LC-MRM-MS for 
translational analysis.  
 
Experimental Conditions 
Blood sample collection and plasma extraction 
Human blood samples were collected from a cohort of twenty healthy donors, twenty 
heart failure with preserved ejection fraction (HFPEF) patients, and twenty heart failure 
with reduced ejection fraction (HFREF) patients, following informed consent. All HFPEF 
patients had an ejection fraction of ≥50% and HFREF patients had an ejection fraction 
≤40%. A volume of 20 mL of blood was collected in a Sterilin tube containing 330 μL of 
Trasylol (= 3000 Kallikrein Inhibitor Units) and 80 μL of 1 M EDTA per 20 mL of blood. 
The blood was mixed before centrifugation at 15 000 g at 4 °C for 30 min. The plasma 
layer was separated from the buffy layer and red blood cells, and stored at -80 °C. 
 
Protein digestion protocols 
Twenty microliters of undepleted human EDTA test sample plasma (Sigma-Aldrich, St. 
Louis, MO) for the comparative configuration part of the study was diluted with 80 μL of 
50 mM ammonium bicarbonate solution and denatured in the presence of 10 μL of 1% 
RapiGest (Waters Corporation, Milford, MA) detergent solution at 80 °C for 45 min. The 
plasma proteins were reduced in the presence of 5 μL of 100 mM dithiothreitol at 60 °C 
for 30 min. and alkylated in the dark in the presence of 6 μL of 200 mM iodoacetamide 
at ambient temperature for 30 min. Proteolytic digestion was initiated by adding 40 μL of 
1 µg/μL sequencing grade, modified trypsin (Promega, Madison, MI) and incubated 
overnight at 37 °C. Breakdown of the acid-labile detergent was achieved in the presence 
of 1% TFA at 37 °C for 45 min. The peptide solutions were centrifuged at 13,000 rpm for 
10 min, and the supernatants collected. 
Patient and donor plasma samples were digested as previously described with minor 
modifications [25]. RapiGest solution was then added to the samples to give a 0.1% final 
concentration and incubated at 80 °C for 45 min. The samples were then reduced with 
100 mM aqueous DTT solution added to give a final concentration of 5 mM prior to 
incubation at 60 °C for 30 min. A 200 mM IAA solution was added to the samples to give 
a final concentration of 10 mM before incubation in the dark at room temperature for 30 
min. A trypsin solution of 1 μg/μL was added to the sample in a 1:50 w/w ratio and 
incubated at 37 °C overnight. Digestion was concluded, and RapiGest cleaved, with the 
addition of neat formic acid to the sample to give a final concentration of 0.5%. The 
plasma samples were centrifuged at 13,000 rpm for 10 min to remove insoluble 
material, and the supernatants collected. 
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LC configurations 
1D nanoscale LC separation of tryptic peptides was performed with a Acquity M-class 
system (Waters Corporation), equipped with a Symmetry C18 5 µm, 2 cm x 180 µm 
precolumn and an HSS T3 C18 1.8 µm, 25 cm x 75 µm analytical RP column (Waters 
Corporation). The samples were transferred with aqueous 0.1% (v/v) formic acid to the 
precolumn at a flow rate of 5 µL/min for 3 min. Mobile phase A was water containing 
0.1% (v/v) formic acid, whilst mobile phase B was acetonitrile containing 0.1% (v/v) 
formic acid. After desalting and preconcentration, the peptides were eluted from the 
precolumn to the analytical column and separated with a gradient of 3-40% mobile 
phase B over 90 min at a flow rate of 300 nL/min, followed by a 2 min column rinse with 
85% of mobile phase B. The columns were re-equilibrated at initial conditions for 20 
min. The analytical column temperature was maintained at 35 ºC. 
Additional, higher throughput experiments were performed with 150 µm × 100 mm 
ionKey/MS micro-fluidics packed with BEH C18 1.7 μm [26]. Gradient conditions were 
from 3-40% B gradient over 45 min at a flow rate of 1 µL/min, followed by a 6 min 
column wash with 85% of mobile phase B. The columns were re-equilibrated at initial 
conditions for 9 min. The analytical column temperature was maintained at ambient 
temperature. Samples were injected/loaded directly on-column or using a precolumn 
configuration. In this instance, the precolumn was 5 cm x 300 µm id, packed with 5 µm 
Symmetry C18 and samples loaded with a flow rate of 15 µL/min for 1 min. Faster 
reversed phase gradient separation, both nanoscale LC and micro-fluidics based, were 
explored but not considered for detailed analysis as (isobaric) interferences or detection 
issues were readily observed, as exemplified in Supplementary Figure 1, hampering 
more detailed comparative configuration analysis. 
 
MS configurations 
Multiple Reaction Monitoring (MRM) analysis was performed using two tandem 
quadrupole mass spectrometers, Xevo TQ-S and Xevo-TQ-S micro, and two hybrid 
quadrupole orthogonal acceleration time-of-flight platforms, Xevo G2-XS Q-ToF and 
Synapt G2-Si (Waters Corporation, Wilmslow, United Kingdom). The Synapt G2-Si 
instrument is equipped with a travelling wave ion, tri-wave ion guide, which comprises 
two stacked ring collision induced dissociation (CID) regions, separated by a travelling 
wave guide that can be used for ion mobility separation. This configuration is described 
in detail elsewhere [6,27]. All experiments were performed in positive electrospray 
ionisation (ESI) mode. The ion source block temperatures and capillary voltages were 
kept constant for all instruments and set to 70 ºC and 3.2 kV. Micro-fluidics interfaced 
experiments were typically conducted with a slightly increased capillary voltage of 3.6 
kV. The N2 cone gas flow and nanoflow gas pressure were 35 L/h and 0.2 bar, 
respectively, whereas the Ar collision gas flow equalled 2 mL/min. The quadrupole and 
time-of-flight analyzers were externally calibrated with NaCsI mixtures from m/z 50 to 
1990. 
A number of instrument and analyzer specific parameters, as well as the acquisition 
types, used in this study are presented in Table 1. Endogenous and stable isotope 
labelled (SIL) peptides were targeted by at least three transitions with a minimum of 10 
data points over a chromatographic peak. Tandem quadrupole dwell and interscan delay 
times were automatically calculated by the operating software based on a minimum 
number of data points specified at half height across a chromatographic peak. Collision 
energies were set at fixed values for the tandem quadrupole instruments and ramped for 
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the time-of-flight instrument. In addition, for the time-of-flight based MRM acquisitions, 
integration and interscan delay times were manually set. Collision energies were ramped 
and initially calculated using the following regression equation: 0.034 times m/z + 3.314 
eV, and further optimized by CID fragmentation evaluation obtained by repeat injections 
of SIL peptides in the absence of matrix. The MRM transitions for both instrument types 
are listed in Supplementary Table 1. 
 
Experimental designs 
Fifteen stable isotope labelled (SIL) peptides (PepScan, Lelystad, Netherlands), 
representing putative blood-based cardiovascular disease protein biomarkers spanning 
over five orders of dynamic concentration range [28], were initially spiked as a dilution 
series from 6.25 amol to 12.5 fmol on-column, in tryptic digested EDTA human plasma. 
The SIL peptides and associated proteins of interest are shown in Table 2, including 
normal plasma protein and molar peptide concentration values [29]. In total, considering 
all LC-MS configurations and column/interface formats, 108 LC-MS experiments were 
conducted. Extended dynamic range experiments were conducted with one of the SIL 
peptides at spike levels ranging from 7.5 amol to 1.5 pmol, in tryptic digested human 
plasma as well. 
The healthy donor, HFPEF and HFREF plasma samples were spiked post-digestion at 
four individual different levels of 0.25, 0.5, 2 and 10 fmol each with the same fifteen SIL 
peptides, analyzed separately, providing multiple, user selectable quantitation levels and 
surrogate technical replicates, mounting to a total of 240 LC-MS experiments (~ 10 days 
of measurement time). 
 
Sulfadimethoxine base sensitivity analysis 
Base sensitivity analysis were conducted with Xevo TQ-S micro and Xevo G2-XS Q-
ToF platforms, both operated in positive ion mode ESI and interfaced to an Acquity H-
class system (Waters Corporation), and sulfadimethoxine (Sigma-Adrich) as the test 
analyte. The source temperature was maintained at 150 ºC, the desolvation temperature 
at 550 ºC, the desolvation gas flow at 1000 L/h, and the capillary voltage set at 4 kV. 
Mobile phase A was aqueous 0.1% (v/v) formic acid/0.05% (v/v) ammonia solution, and 
mobile phase B acetonitrile containing 0.1% (v/v) formic acid. The column was 2.1 x 50 
mm packed with BEH 1.7 µm stationary phase (Waters Corporation), operated at 0.8 
mL/min, and maintained at 40 °C. 
 
Informatics 
Tandem quadrupole and high resolution Q-ToF LC-MS peptide MRM data were 
quantified with either TargetLynx (Waters Corporation) or Skyline [30], and analyzed 
and visualized with Spotfire v6.0.0 (TIBCO software, Boston, MA). All statistical analyses 
were conducted with SIMCA (v14, MKS Umetrics AB, Umeå, Sweden) or IBM SPSS 
statistics v22 (IBM Corporation, Armonk, NY). 
Orthogonal partial least squares-discriminant analyses (OPLS-DA) were performed on 
the candidate peptides as a ratio to their labelled standard and all data Pareto scaled. 
Sample runs that deviated significantly from the Hotelling’s T2 95% confidence interval 
were excluded and the model refitted. Peptides considered as contributing to the 
supervised separation of groupings were identified by consultation of the accompanying 
S-plot. OPLS-DA models were produced for control subjects vs. those with heart failure, 
and for heart failure with reduced ejection fracture vs. preserved ejection fraction. 
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Pair-wise comparisons for identified peptides of interest were performed by the Mann 
Whitney U test for independent samples. Logistic regressions were performed to 
calculate the probabilities of heart failure prediction for each individual peptide of 
interest, and as a combination of all these peptides. Receiver operator characteristic 
curves were produced using these probabilities and the areas under the curve were 
calculated. All tests with a two-tailed p value of <0.05 were deemed as statistically 
significant. 
 
Results and discussion 
Biomarker discovery and validation are the first steps in understanding disease and 
finding surrogate markers for drug development. Validation is challenged since it 
requires the analysis of a large number of samples with high-throughput, but also with 
high sensitivity, reproducibility, robustness, accuracy and precision over a large dynamic 
range. Targeted LC-MS based assays have been shown previously to afford protein 
quantitation with the reproducibility and throughput required in order to improve 
biomarker acceptance [31]. MRM based assays on tandem quadrupole instruments have 
been the primary technology used, but more recently higher mass resolution system and 
those incorporating and hybridising ion mobility with high resolution mass spectrometry 
have been described. 
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) designed a series of 
interrelated studies to assess the reproducibility and quantitative characteristics of 
tandem/triple quadrupole based MRM assays [32-35], as well as developing reference 
materials, software tools, and guidelines for data sharing. Tandem and triple quadrupole 
mass spectrometers were applied in these studies since they are the quantitation ‘gold 
standard’, providing a high speed multiplexing capability compared to other analyzer 
types, a large linear dynamic range of quantitation, and have good sensitivity, signal-to-
noise and specificity. Despite this, tandem quadrupole based MRM has been challenged 
and criticized from both a biological and technical perspective, and mass spectrometry 
based alternatives, using high-resolution mass analyzers, explored [23,36-39]. 
Notwithstanding these challenges, tandem/triple quadrupole mass spectrometers have 
been successfully applied for the quantitative analysis of proteins. As an example, Carr 
et al. [40] reported on the efficient quantitation of low-abundance plasma proteins, 
representing an 800-plex MRM based LC-MS assay, run in a single analysis, comprising 
2400 transitions with retention time scheduling to monitor 400 unlabeled and heavy 
labelled peptide pairs. 
 
Analytical performance and ion transmission 
One of the evaluated tandem quadrupole MS platforms in this study was also used in 
the CPTAC studies [32-35] and numerous other biomarker studies including the 
previously mentioned highly multiplexed study [40]. This platform will be used as the 
base for the comparative experiment, with emphasis on sensitivity, throughput/speed, 
selectivity, precision and accuracy for the quantitation of peptides and proteins. From a 
theoretical perspective, a number of parameters need to be considered when comparing 
tandem mass spectrometry geometries. The first mass analyzer of all platforms 
comprises a quadrupole ion guide. The transmission of these devices typically ranges 
from 50 to 80% at 0.7 Da FWHM resolution [41]. Within a tandem quadrupole 
configuration, the overall transmission would equal the product of the transmission of 
the individual analysers. In a hybrid quadrupole orthogonal acceleration time-of-flight 
mass spectrometer, the transmission across a narrow m/z range can approach 100% if 
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the pusher is synchronized with the output from the collision cell [42]. An approach has 
previously been described that can maximise the duty cycle of the orthogonal 
acceleration time-of-flight (oa-ToF) to close to 100% across the m/z range using the 
synchronization of the ion mobility separation stage with the pusher of the oa-ToF [43]. 
Thus, dependent upon the configuration, an oa-ToF analyzer is close to the transmission 
of a quadrupole ion guide operated at unit resolution. However, compounding duty cycle 
are interscan delay times and the number of measured transitions. Quadrupole interscan 
delay times can be as small as 1 ms, not noticeably affecting transmission, whereas 
currently oa-ToF interscan delay times are around 5-15 ms, resulting in lower duty cycle 
at higher acquisition rates. 
In terms of absolute sensitivity, in practice, tandem/triple quadrupole and (hybrid) 
oa-ToF performances can be found to be comparable. For example, for a single transition 
for the analysis of sulfadimethoxine the lower limits of detection (LLOD) and quantitation 
(LLOQ) for a tandem quadrupole (Xevo TQ-S micro) and an oa-ToF (Xevo G2-XS QTof) 
platform were both found to be equal to 5 and 10 µg on-column. Shown in 
Supplementary Figure 2 are the MRM chromatograms for the transition(s) of 
sulfadimethoxine on both MS platforms, illustrating that the base performance/sensitivity 
and ion transmission for the analysis of a single compound in isolation are almost 
identical, under the same experimental conditions. The next paragraphs will demonstrate 
how the evaluated geometries compare for the multi-analyte MRM analysis of 
endogenous and SIL peptides spiked in undepleted digested plasma matrix and that the 
single analyte observations also hold for multi-analyte experiments. 
 
Transition selection and optimization 
The collision cells used in all evaluated MS geometries utilize similar low energy CID 
fragmentation characteristics. Shown in Figure 1, as an example, are the full scan 
MS/MS spectra for one of the SIL peptides, namely FPEVDVLTK-13C615N2. The top (A) 
pane illustrates a tandem/triple quadrupole MS/MS spectrum, the middle (B) pane an 
oa-ToF equivalent, and the bottom (C) pane an enhanced duty cycle (EDC) oa-ToF full 
scan spectrum. As can be noted, the profiles of the tandem quadrupole and oa-ToF 
MS/MS spectra share great similarity, suggesting that transitions can be derived from 
oa-ToF based discovery experiments and translated to tandem MS geometry 
independent MRM transitions [44]. Also shown is that the EDC oa-ToF MS/MS spectrum, 
centering at m/z 682.4, is promoting over a relative wide m/z range of a few hundred Th 
wide across the product ion range of interest, thereby somewhat skewing the relative 
abundances of the product ions and their associated ratios, but significantly increasing 
sensitivity. Maximum duty cycle is retained in this way of operating EDC oa-ToF MRM 
acquisitions since only a single m/z value is synchronised. The spectra shown in panels B 
and C of Figure 1 have been scaled to the m/z 682.4 product ion intensity values to 
afford direct comparison, indicating a gain in signal of approximately five for this 
particular ‘transition’. 
Fifteen peptides, representing thirteen proteins were selected from the study by 
Domanski et al. [28], covering more than five orders of plasma protein concentration 
dynamic range. Selection rules taken into consideration were concentration, amino acid 
composition and sequence length. The fifteen SIL peptide equivalents listed in Table 1 
were pooled at equimolar levels and analyzed by both data independent analysis (DIA; 
MSE-style) [45,46] and precursor isolated MS/MS experiments in the absence of matrix 
to examine fragmentation behaviour and product ion distribution. Only y” fragment ions 
were considered and the CID collision energies and ramps optimized for maximum 
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product ion intensity distribution and circumventing over or under fragmentation using 
the collision energy regression rules described in the section Experimental Conditions as 
the initial collision energy values. A minimum of three transitions/product ions per 
peptide were selected, one peptide excluded. The selected precursor and product ion 
target masses, constituting the MRM transitions, are overviewed in Supplementary Table 
1. The endogenous target masses were determined by calculation. EDC m/z selection 
was based upon the relative product ion intensity (abundance) of a fragment m/z value 
within the region of interest (precursor m/z < EDC m/z < ymax m/z). In practice this is 
close to the center of the m/z range, obtained from either an experimental DIA or 
MS/MS product ion spectrum. 
 
Technical and experimental variation 
Several sources contribute to assay variation, including technical, experimental, and 
biological variation (sampling, sample preparation (solid phase extraction, digestion, 
pipetting, LC-MS, etc.). The variation, precision and confidence level are significant 
factors in determining that a given study has appropriate power and are critical when 
designing a translational biomarker study. The imprecision, bias, and total allowable 
error, calculated from data on within-subject and between-subject biologic variation for 
clinical assays, including plasma proteins, have been populated in a database [47,48], 
and recently updated [47]. Accessing the biological protein plasma concentration 
variation of a population and the individual component and summed technical 
experimental variation by means of LC-MS is beyond the scope of this study; however, 
variation should be considered when developing and specifying quality requirements in 
relation to the size of the cohort to be studied. Table 3 summarizes the biological 
variation of a number of the proteins of which the peptides have been examined in this 
study as determined by accepted clinical assays. The variation is greatly protein 
dependent, which will determine the consideration of LC-MS as an alternative and viable 
technology, for example where immunoassays fail [49], as well as cohort/sample size 
[31]. As an example of technical variation LC-MS tandem quadrupole MRM precision was 
assessed to provide an appreciation of the application of LC-MS in translational studies. 
More extensive experimental variation study results are published in more detail 
elsewhere [50], including digestion [51-53], which is widely quoted and seen as a major 
source of variation. Three SIL peptides were spiked in fifty independent, undepleted, 
tryptic digested plasma samples and the absolute and relative transition abundances 
measured. The results shown in the top (A) pane of Figure 2 illustrate the raw summed 
abundances are sample dependent and different trends can be observed for the three 
peptides of interest. The latter can be explained by the fact that the (biological) 
background will vary per unit (chromatographic) time as the matrices are different for 
every sample but would mimic the effects observed in a larger cohort study. The left 
bottom (B) pane summarizes the result in box-and-whisker format with uncorrected CV 
values ranging from about 10 to 30%. The middle bottom pane (C) illustrates the 
consistency of the relative abundances of the transitions (intensity of the most abundant 
transition/intensity sum of all transitions). This characterizes the magnitude of internal 
standard correction, in terms of reducing CV values from raw to relative values, and 
reduces the CV values by a factor of two to five. Normally, this would be achieved by 
contrasting the abundances of the endogenous peptides of interest with those on its SIL 
counterpart and assessed with informatics tools such as m-prophet [54] or AuDIT [55]. 
The bottom right (D) pane results illustrate retention time reproducibility numbers, 
which was on average close to 0.5% CV. 
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Throughput and speed of analysis 
The fastest gradient separations possible were employed without introducing isobaric 
interferences for the fifteen SIL peptides monitored for both LC platforms. As the micro-
fluidics interface is operated at a higher flow-rate, and the number of connectors and 
connection lines reduced compared to a typical nanoscale LC set-up, system volumes are 
more quickly ‘swiped’, providing reduced gradient delivery delays and faster column 
conditioning. Moreover, extra-column volumes will be less critical at higher flow-rates. 
Typical nanoscale LC and micro-fluidics tandem quadrupole MRM chromatograms for 125 
amol SIL peptides injected on-column are shown in Supplementary Figure 3, illustrating 
an average increase in speed of analysis of 1.9 for 150 µm inner diameter (id) micro-
fluidics vs. 75 µm id nanoscale LC tryptic peptide separations at nearly identical linear 
mobile phase velocities. The complete experimental injection-to-injection cycle times 
were 1 and 2 h for the micro-fluidics and nanoscale LC based separations, providing a 2-
fold increase in throughput for the micro-fluidics experiments. Average peak widths at 
half-height W0.5 were 0.07 and 0.12 min, respectively, mounting to similar peak capacity 
approximations of 320 and 375, assuming that the chromatographic separations spaces 
were 45 and 90 min. Retention time reproducibility (data not shown) was in both cases 
better than 1%. 
 
Quantitative comparison of platforms and column geometries 
The linear response and the peak-to-peak signal-to-noise (S/N) at a given 
concentration level were determined and the lower limit of detection estimated for a 
dilution series of the fifteen SIL peptides, representing thirteen proteins, spiked into 
undepleted, tryptic digested plasma. The injected plasma digest on-column amount, 
assuming a normal total protein concentration of 70 g/L, equalled 140 ng. S/N values 
were determined at 12.5 amol injected on-column for the 75 µm id nanoscale LC based 
experiments and at the 125 amol level for the 150 µm id micro-fluidics LC-MS 
separations, respectively. The MS response and assay sensitivities were initially tested 
from 6.25 amol to 12.5 fmol for the nanoscale LC based experiments and from 62.5 
amol to 12.5 fmol for the micro-fluidics separations, with the tested dynamic range 
extended for a subset of configurations, including additional technical LC-MS replicates, 
as described below. 
The results are summarized in Table 4 and Supplementary Table 2. Within the tested 
range, exceeding three orders of concentration dynamic range, all mass spectrometers 
demonstrated 1/x weighted linear behaviour with r2 regression correlation coefficient 
values of 0.9909 or greater for all SIL peptides. Similarly, the S/N values measured at 
the 12.5 amol and 125 amol spike level were found to be comparable for the majority of 
the SIL peptides measured with all LC-MS configurations, ranging from 2 to 30 for the 75 
µm id nanoscale LC setup, and 2 to 100 for the 150 µm id micro-fluidics configuration, 
respectively. The median and average lower limit of detection (LLOD) values, across all 
MS platforms equalled 5 and 8 amol for the 75 µm id nanoscale LC experiments, and 20 
and 39 amol for the 150 id micro-fluidics LC-MS. The experiment also afforded 
calculation of the concentration of some of the endogenous peptides that were within the 
measured dynamic range. The results shown in Table 5 overview the determined 
concentrations of the endogenous peptides (proteins) for the 75 µm id nanoscale LC 
based experiments and Supplementary Table 3 for the 150 µm id micro-fluidics LC-MS 
separations, respectively. The concentration and coefficient of variation (CV) were 
calculated for each individual SIL spike-level, representing a multi-level single point 
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average and error estimate. The average CV values, across all MS platforms as well, for 
the nanoscale LC and micro-fluidics experiments were found to be equal to 8.6 ± 3.5% 
and 10.3 ± 4.7%, respectively. The MRM data of the LC platform/configuration 
comparative part of the study are provided in ‘Supplementary Information – LC-MS 
Configuration Comparison’. 
 
Extended dynamic range experiments 
Despite quite similar and impressive levels of analytical performance, the best 
overall/combined performance in terms of CV precision and throughput, see previous 
sections, was obtained with the 150 µm id micro-fluidics interface in combination with 
one of the tandem quadrupole mass spectrometers. The dynamic range of the assay was 
extended and the detection of the lower abundant target peptides improved by using a 
trap-column based LC configuration of which the details are provided in the Experimental 
section. This column configuration allows for the loading of five-fold more protein plasma 
digest without affecting the chromatographic performance of the system (data not 
shown) and afforded the detection of fourteen of the fifteen target peptides/proteins in 
undepleted plasma. Linear response was observed for LGPLVEQGR-13C615N4 from 15 amol 
to 1.5 pmol injected on-column in the presence of matrix, representing five orders of 
magnitude of linear LC-MS response, as illustrated in Supplementary Figure 4, with a 
median %CV value, for the individual SIL standard levels, of 5.5%, and a r2 regression 
correlation coefficient of 0.9842. 
 
Mobility enabled MRM methods 
IM enabled oa-ToF MRM acquisition modes can provide either increased selectivity or 
sensitivity. These modes could be useful for lower level peptides that challenge assay 
specificity and are briefly described with example results presented. With the mobility 
enabled oa-ToF platform, the collision cell/mobility separation region comprises three 
stacked ring ion guide devices placed in series (tri-wave). The first region can be used to 
either trap ions or conduct CID fragmentation. Within the second region, the ions, either 
precursor or product ions, dependent on the use of the trap region, undergo mobility 
separation. In the third region, the ions are either transferred to the oa-ToF analyzer or 
CID fragmented. The device has been described in detail elsewhere [26,56,57], as well 
as alternative uses of stacked ring ion guides, including electron transfer dissociation 
[58] and top-down type studies [59]. The two cases described here are graphically 
summarized in Figure 3. The top (A) pane illustrates a case where ion mobility 
separation is achieved in the second region and CID conducted in the third region, 
aiming at achieving additional assay selectivity. The bottom (B) pane demonstrates ion 
mobility separation at the product ion level which is aimed at increasing sensitivity 
across the complete m/z fragment ion range by optimizing the duty cycle of the 
instrument. In short, product ions are trapped within the first region of the tri-wave 
device and gated into the high-pressure ion mobility region where they are separated 
according to their gas phase mobility, which is predominantly determined by mass, 
charge, size, and shape. As a result, fragment ions of the same mobility exit the cell as a 
series of compact packets. Hence, by synchronizing the pusher pulse that accelerates the 
fragment ions into the oa-ToF mass analyzer with the arrival of product ions into the 
pusher region, fragment ions are sequentially injected into the ToF analyzer with greatly 
enhanced duty cycle (~ 85%) across the mass scale [43]. 
The benefit of the latter case is illustrated in Figure 4, showing typical sub 100 amol 
on-column results obtained with oa-ToF MRM data collected in normal MRM mode using 
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EDC in the top (A) pane and with product ion IM separation in the bottom (B) pane. Data 
were normalized to the endogenous level to account for any experimental LC-MS 
variation and collected in so-called isotope stripping mode, whereby only isotopic 
information is stored for a pre-defined set of product ions, reducing file size significantly 
without losing quantitative information. As can be seen, the mobility enabled method 
provided better sensitivity. The effect of EDC can be noted as illustrated by the relative 
high intensity of the high mass vs. the low mass product ions, which was aimed at 
sacrificing the low m/z product ion region nearly completely by promoting the oa-ToF 
duty cycle for the more specific high m/z product ions. An example of the former 
mentioned IM enabled oa-ToF MRM method, where additional precursor and product ion 
separation can be achieved of co-isolated peptides that differ in ion mobility 
characteristic or CCS value, prior to CID in the transfer region of the tri-wave 
mobility/collision cell, is shown in Figure 5. The application of these highly selective oa-
ToF modes of acquisition for the quantitation of peptides and proteins will be published in 
a separate communication. 
 
Application results 
Heart failure represents a heterogeneous clinical population for which biomarkers are 
sparse. The aetiology of the disease also means that the phenotypic changes are likely to 
be multifactorial. As a proof of principle and test of overall sensitivity to classify this 
heterogeneous disease, twenty healthy controls, twenty patients with HFPEF and twenty 
heart failure patients with HFREF were analyzed. For this particular application, the 
micro-fluidics interface, equipped with a pre-column, was used in combination with one 
of the tandem quadrupole mass spectrometers, as it provided the best combination of 
throughput, loadability, sensitivity, precision and linearity. The micro-fluidics gradient 
conditions were adjusted to the previously described experiments, namely from 2 to 
30% B in 45 min at 35 °C, to increase chromatographic resolution. Multivariate analysis 
of proteins showed that patient samples could be classified using OPLS-DA, using the 
data and results obtained from one of the SIL spike level (10 fmol) experiments, as 
illustrated by the scores distribution/summary in Figure 6. Partial separation of healthy 
controls and HF (combined HFPEF and HFREF) can be observed. Fit (R2) and prediction 
(Q2) values of 0.52 and 0.38 were obtained, respectively, for the developed model. The 
three proteins contributing mostly to the separation, as identified by analyzing the 
loadings distributions, covariance vs. correlation, were Apolipoprotein A-1 (APOA), 
Plasma protease C1 inhibitor (SERPING1) and C-reactive protein (CRP). Univariate 
analysis of these three proteins showed significant changes in levels between the groups, 
as summarized in Figure 7A-C. Good discriminant power was obtained by combining 
these protein surrogate peptides, with an area under the receiver operating 
characteristic curve of 0.937 obtained as illustrated in Figure 7D. Previous work 
demonstrated that ApoA1 is potentially protective in HF, so the lower observed levels in 
the HF group would be consistent [60]. CRP is well known to increase with heart failure 
[61], and plasma protease C1 inhibitor may well be indicative of remodelling, which is a 
clear pathophysiological mechanism in heart failure. Distinct separation between all three 
groups, namely control, HFPEF and HFREF, was not obtained with the selected subset of 
peptides, however, a partial separation model could be developed for HFREF and HFPEF, 
see Supplementary Figure 5. These results suggest that a classification model can be 
achieved with a multi-analyte LC-MRM-MS assay, using tandem quadrupole mass 
spectrometry combined with micro-fluidics, and a subset of three proteins from the 
thirteen proteins examined. Improvements to the model would necessitate a larger 
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cohort of samples or the use of other peptides/proteins, which was outside the scope of 
this study. However, the strength of the model and the biological processes identified as 
contributing to the model indicate that this approach may yield successful opportunities 
for biomarker research. The MRM data of the biological part of the study are provided in 
‘Supplementary Information – Application Results’. 
 
Conclusions 
 
LC-MRM-MS has been adopted and widely applied in translational biomarker studies due 
to the inherent speed of developing a multiplexed assay that can be deployed with 
relatively high sensitivity and throughput. In this study, building upon previous studies, 
the effect of both the LC scale and the choice of MS platform has been investigated. In 
biomarker discovery, many performance studies have been conducted using extensively 
high performance LC-MS systems. However, the technical and performance challenges in 
biomarker translation studies are different and require a robust and reliable platform, 
with good quantitative precision that can analyse much larger cohorts of samples. The 
results presented show that with regard to the LC component, despite nanoscale LC 
being the predominant separation technology in quantitative protein biomarker studies, 
it was found that a larger 150 µm inner diameter scale micro-fluidic based system has 
the required sensitivity and quantitative performance, combined with throughput 
characteristics required for quantitative translational studies.  
In the case of the MS platform, the use of higher resolution systems can have 
significant benefits in the targeted analysis of biomarkers in biological matrices. The 
elevated resolution can often be translated in increased specificity and therefore a more 
reliable measure of a peptide and hence proteins abundance. In this study, looking at a 
range of peptides in undepleted human plasma, the sensitivity was found to be very 
comparable between the modern tandem quadrupole and the quadrupole time-of-flight 
systems, but the combination of a high sensitivity tandem quadrupole with a micro-
fluidic inlet provided the best coefficient of variation, throughput and sensitivity/signal-
to-noise. It may be surprising, in some regards, that the elevated resolution of the 
second mass analyser of the time-of-flight systems does not translate to into improved 
quantitative performance, but in this study the peptides, even at levels close to their 
lower limit of quantitation provided a linear response with all MS platforms. 
The preferred instrument configuration was used for the analysis of the selected 
peptides, and hence proteins, originating from heart failure disease patients, and 
compared to matched control samples. This preliminary study was designed to test the 
overall sensitivity and to classify this heterogeneous disease, resulting in separation of 
the two disease groups from the control group and partial separation of the two disease 
phenotypes. The multiplex assay will be further tested on a larger cohort of heart failure 
patients to test the classification. This study has shown that the applied LC-MS platform 
demonstrates suitable throughput and sensitivity to accommodate analysis of much 
larger cohorts that are typical in cardiovascular biomarker discovery (>1000 patient 
samples). Moreover, what is particularly attractive about this configuration is that the 
step from initial discovery to verification of initial candidates can be rapidly executed 
using a targeted MS approach rather than an alternative such as immunoassay or 
western blot which are potentially more expensive, less specific and consume more 
sample than the methods described here. Thus, the transition from discovery to 
validation is greatly accelerated. Additionally, it is plausible that further candidates could 
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be integrated with relative ease, providing future flexibility and with little detriment to 
throughput.  
 LC-MS technology continues to mature and the current technology has the required 
analytical performance to make large-scale biomarker translation studies a reality. This 
combined with the ability to build highly flexible, multiplexed assays will ensure that the 
technology will have an impact in the detection and monitoring of complex 
heterogeneous diseases. 
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Captions 
 
Figure 1. Full scan tandem quadrupole MS/MS (A), oa-ToF MS/MS (B) and EDC oa-ToF 
MS/MS (C) spectra of FPEVDVLTK-13C615N2. The precursor and EDC oa-ToF m/z values 
were 528.3 and 682.4, respectively. The B and C panels are scaled to absolute m/z 
682.4 product ion intensity values with only the product ion masses in the range of 
interest transmitted with EDC oa-ToF MS/MS.   
 
Figure 2. Raw summed tandem quadrupole MRM transition abundances as a function of 
replicate experiments (n = 50) for SIL peptides FPEVDVLTK-13C615N2, TAAQNLYEK-
13C615N2, and TGLQEVEVK-13C615N2 spiked at a fixed level in different, independent 
undepleted plasma digest samples (A), raw summed transition intensity variability (B), 
intra peptide normalized transition intensity variability (C), and peptide retention time 
variability (D). 
  
Figure 3. Mobility enabled oa-ToF MRM methods. (A) Precursor ion mobility separation 
followed by transfer CID including EDC for selected target masses and (B) trap CID 
followed by product ion mobility separation. 
 
Figure 4. Standard oa-ToF MRM with EDC (A) and trap CID followed by product ion 
mobility separation (B) for 62.5 amol of SIL labeled GYSIFSYATK-13C615N2 injected on-
column, monitoring fragments y5 (m/z 577.3), y6 (m/z 724.4), y7 (m/z 837.5), and y8 
(m/z (EDC) 924.5). See section Experimental Conditions and Supplementary Table 1 for 
additional experimental and MRM details. 
 
Figure 5. (A) Precursor isotope IM separation of two peptides with A0 m/z 856.8 
(spheres) and A0 m/z 857.0 (squares) co-eluting and co-isolated at 78.6 and 78.5 min, 
respectively, followed by (B) IM separation of an associated product ion to both 
precursors with m/z 527.3. A third product ion with m/z 528.3, originating from 
precursor m/z 856.8 was detected (not annotated) that partially m/z overlapped with the 
isotopes of the 527.3 product ion but was separated in the IM domain. See section 
Experimental Conditions for additional experimental and MRM details. 
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Figures 6. Multivariate OPLS-DA analysis showing the separation and classification of 
patient and control samples. Circle = normal healthy patients; triangles = heart failure 
patients (HFPEF or HFREF). The model indicates that disease can be classified using a 
multiplexed tandem quadrupole LC-MRM-MS based assay. 
 
Figure 7. Univariate analysis of ApoA1 (A), CRP (B) and SERPING1 (C) in HFPEF and 
HFREF and receiver operating curve performance analysis of peptide surrogates for 
Apo1, CRP and SERPING1 (D), respectively. 
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Table 1. Configuration and MRM method overview. 
 
configuration 
   instrument 
acquisition 
mode 
Q2 (Da)/ ToF 
(FWHM) resolution 
selectivity parameters 
Tandem quadrupole 
   Xevo TQ-S 
   Xevo TQ-S micro 
 
Quadrupole time-of flight 
   Xevo G2-XS QTof 
   Synapt G2-Si 
 
 
 
MRM 
MRM 
 
 
ToF MRM/EDC 
ToF MRM/EDC 
IMp-MRM/EDC 
MRM-IMf 
 
0.7 
0.7 
 
 
25,000 
25,000 
25,000 
25,000 
 
tr, transition 
tr, transition 
 
 
tr, transition, m/z 
tr, transition, m/z 
tr, td, transition, m/z 
tr, transition, m/z 
 
Q1 resolution 0.7 Da for all instruments/geometries 
ToF MRM high resolution separation and accurate mass detection fragment ions (Q1 isolation, IMS, 
followed by ‘transfer’ CID and EDC) 
EDC enhanced duty cycle (synchronization of pusher in QTof geometries of the time-of-flight 
analyzer for selected target m/z values/ranges as ions are released from the collision 
cell/region) [48] 
IMp-MRM ion mobility separation peptide precursor ions pre-CID (Q1 isolation, IMS, followed by 
transfer CID and EDC) 
MRM-IMf ion mobility separation fragment ions post-CID (Q1 isolation, trap CID, followed by IMS; 
affords synchronization of pusher in QTof geometries of the time-of-flight analyzer over the 
complete m/z range, providing near 100% duty cycle for all product ions) [51] 
tr retention time (s) 
td drift time (s) 
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Table 2. Target peptide sequences and proteins, including normal amount and molar concentration plasma levels. 
 
peptide sequence entry name primary gene name normal plasma 
concentration (ng/mL) 
peptide amount 
 (nmol/mL plasma) 
LVNEVTEFA[K] 
ATEHLSTLSE[K] 
TGLQEVEV[K] 
FPEVDVLT[K] 
FQPTLLTLP[R] 
TAAQNLYE[K] 
LGPLVEQG[R] 
AAAATGTIFTF[R] 
EANYIGSD[K] 
ESDTSYVSL[K] 
GYSIFSYAT[K] 
GFYFNKPTGYGSSS[R] 
LVNVVLGAHNV[R] 
ITLYG[R] 
SYPGLTSYLV[R] 
ALBU_HUMAN 
APOA1_HUMAN 
CO3_HUMAN 
APOB_HUMAN 
IC1_HUMAN  
APOC2_HUMAN 
APOE_HUMAN 
IPSP_HUMAN  
SAA1_HUMAN 
CRP_HUMAN 
 
IGF1_HUMAN 
PRTN3_HUMAN 
NGAL_HUMAN 
 
ALB 
APOA1 
C3 
APOB 
SERPING1 
APOC2 
APOE 
SERPINA5 
SAA1 
CRP 
 
IGF1 
PRTN3 
LCN2 
41,000,000 
1,400,000 
1,300,000 
730,000 
137,000 
33,000 
40,000 
4,400 
4,000 
2,300 
 
144 
23 
87 
 
620 
50 
7.0 
1.4 
2.6 
3.7 
1.2 
0.10 
0.34 
0.10 
 
0.019 
0.000949 
0.00423 
 
 
[K] = 13C615N2 labelled; [R] = 13C615N4 labelled 
 
ALBU_HUMAN = serum albumin; APOA1_HUMAN = Apolipoprotein A-1; APOB_HUMAN = Apolipoprotein B-100; APOC2_HUMAN = Apolipoprotein C-II; APOE_HUMAN = 
Apolipoprotein E; CO3_HUMAN = Complement C3; CRP_HUMAN = C-reactive protein; IGF1_HUMAN= Insulin-like growth factor I; PRTN3_HUMAN = Myeloblastin; 
NGAL_HUMAN = Neutrophil gelatinase-associated; IC1_HUMAN = Plasma protease C1 inhibitor; IPSP_HUMAN = Plasma serine protease inhibitor; SAA1_HUMAN = Serum 
amyloid A-1 protein 
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Table 3. Biological variation [48]. 
 
entry name protein name biological variation # references 
  CVI CVG  
ALBU_HUMAN 
APOA1_HUMAN 
APOB_HUMAN 
CRP_HUMAN 
CO3_HUMAN 
IGF1_HUMAN 
Serum albumin 
Apolipoprotein A-1 
Apolipoprotein B-100 
C-reactive protein 
Complement C3 
Insulin-like growth factor I 
3.2 
6.5 
6.9 
42.2 
5.2 
14.6 
4.8 
13.4 
22.8 
76.3 
15.6 
45.4 
24 
11 
9 
3 
2 
2 
 
CVI = within-subject (intra-individual) coefficient of variation; CVG = between-subject (inter-individual) 
biological variation 
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Table 4. Quantitative response, S/N and estimated LLOD of fifteen SIL peptides spiked into undepleted, tryptic digested human serum 
using tandem quadruple and oa-ToF mass spectrometry in combination with nanoscale LC (see section Experimental for details). The 
levels tested ranges from 6.25 amol to 1.25 fmol on-column. 
 
peptide sequence r2 S/N @ 12.5 amol on-column  estimated LLOD 
 MRM1 MRM2 oa-ToF1 oa-ToF2 MRM1 MRM2 oa-ToF1 oa-ToF2 MRM1 MRM2 oa-ToF1 oa-ToF2 
LVNEVTEFA[K] 
ATEHLSTLSE[K] 
TGLQEVEV[K] 
FPEVDVLT[K] 
FQPTLLTLP[R] 
TAAQNLYE[K] 
LGPLVEQG[R] 
AAAATGTIFTF[R] 
EANYIGSD[K] 
ESDTSYVSL[K] 
GYSIFSYAT[K] 
GFYFNKPTGYGSSS[R] 
LVNVVLGAHNV[R] 
ITLYG[R] 
SYPGLTSYLV[R] 
 
median 
0.9957 
0.9931 
0.9956 
0.9959 
0.9995 
0.9986 
0.9994 
0.9989 
0.9949 
0.9981 
0.9990 
0.9984 
0.9952 
0.9987 
0.9997 
- 
0.9955 
0.9999 
0.9995 
0.9983 
0.9994 
0.9993 
0.9994 
0.9915 
0.9986 
0.9995 
0.9974 
0.9980 
0.9999 
0.9991 
0.9997 
0.9985 
0.9992 
0.9965 
0.9986 
0.9998 
0.9992 
0.9956 
0.9982 
0.9995 
0.9989 
0.9983 
0.9966 
0.9986 
0.9976 
0.9966 
0.9909 
0.9976 
0.9998 
0.9989 
0.9996 
0.9966 
0.9999 
0.9993 
0.9985 
0.9992 
0.9973 
- 
0.9955 
0.9961 
3 
2 
8 
6 
10 
5 
20 
- 
5 
5 
5 
- 
3 
10 
- 
 
5 
- 
5 
10 
5 
15 
4 
30 
10 
8 
5 
10 
20 
4 
10 
- 
 
10 
5 
5 
10 
6 
10 
10 
20 
8 
3 
10 
10 
4 
- 
12 
2 
 
9 
2 
8 
10 
10 
6 
8 
30 
8 
6 
10 
8 
4 
- 
10 
3 
 
8 
10 
20 
10 
10 
6 
10 
2 
20 
5 
5 
5 
15 
10 
3 
20 
 
10 
- 
5 
2 
10 
3 
5 
2 
10 
10 
4 
3 
3 
10 
3 
30 
 
5 
5 
5 
3 
5 
5 
3 
2 
5 
10 
3 
3 
10 
50 
3 
15 
 
5 
15 
5 
5 
5 
6 
4 
1 
4 
5 
4 
5 
10 
- 
5 
10 
 
5 
 
r2 1/x weighting; peak-to-peak S/N; [K] = 13C615N4 labeled; [R] = 13C615N2 labeled; - = not calculated (isobaric interfering components or insufficient sensitivity) 
MRM1 = Xevo TQ-S micro tandem quadrupole; MRM2 = Xevo TQ-S tandem quadrupole; oa-ToF1 = Xevo G2-XS QTof hybrid oa-ToF; oa-ToF2 =Synapt G2-Si hybrid oa-ToF 
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Table 5. Determined plasma concentration of seven target peptides, representing six proteins, with %CV values using tandem quadruple 
and oa-ToF mass spectrometry in combination with nanoscale LC (see section Experimental for details). 
peptide sequence 
plasma concentration (n = 11) 
fmol/140 ng digested plasma 
%CV 
 MRM1 MRM2 oa-ToF1 oa-ToF2 MRM1 MRM2 oa-ToF1 oa-ToF2 
TGLQEVEVK 
FPEVDVLTK 
FQPTLLTLPR 
TAAQNLYEK 
LGPLVEQGR 
ESDTSYVSLK 
GYSIFSYATK 
2.86 
1.11 
0.090 
0.77 
0.40 
0.099 
0.025 
2.73 
1.18 
0.11 
0.79 
0.38 
0.10 
0.030 
3.2 
1.2 
0.12 
0.81 
0.44 
0.10 
0.031 
4.5 
1.3 
0.13 
1.1 
0.57 
0.11 
0.030 
11.1 
5.4 
4.4 
6.2 
8.4 
12.0 
18.0 
5.4 
5.1 
4.7 
5.3 
5.3 
5.5 
10.4 
8.4 
13.1 
11.2 
9.3 
10.5 
10.7 
13.4 
11.5 
6.4 
10.2 
10.9 
4.1 
5.8 
7.0 
 
MRM1 = Xevo TQ-S micro tandem quadrupole; MRM2 = Xevo TQ-S tandem quadrupole; oa-ToF1 = Xevo G2-XS QTof hybrid oa-ToF; oa-ToF2 =Synapt G2-Si hybrid oa-ToF 
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TAAQNLYEK 23.6 
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Figure 7. Mbasu et al. 
Advances in Quadrupole and Time-of-Flight Mass Spectrometry for Peptide MRM based ... 
Supplementary Table 1. MRM transition overview tandem quadrupole and oa-ToF MRM experiments. 
peptide sequence 
precursor m/z 
[charge] 
fragment m/z 
[fragment ion type] 
EDC m/z* 
  1 2 3 4 5  
LVNEVTEFAK 
LVNEVTEFA[K] 
ATEHLSTLSEK 
ATEHLSTLSE[K] 
TGLQEVEVK 
TGLQEVEV[K] 
FPEVDVLTK 
FPEVDVLT[K] 
FQPTLLTLPR 
FQPTLLTLP[R] 
TAAQNLYEK 
TAAQNLYE[K] 
LGPLVEQGR 
LGPLVEQG[R] 
AAAATGTIFTFR 
AAAATGTIFTF[R] 
EANYIGSDK 
EANYIGSD[K] 
ESDTSYVSLK 
ESDTSYVSL[K] 
GYSIFSYATK 
GYSIFSYAT[K] 
GFYFNKPTGYGSSSR 
GFYFNKPTGYGSSS[R] 
LVNVVLGAHNVR 
LVNVVLGAHNV[R] 
ITLYGR 
ITLYG[R] 
SYPGLTSYLVR 
SYPGLTSYLV[R] 
575.3 [2+] 
579.3 [2+] 
608.3 [2+] 
612.3 [2+] 
501.8 [2+] 
505.8 [2+] 
524.3 [2+] 
528.3 [2+] 
593.4 [2+] 
598.4 [2+] 
519.3 [2+] 
523.3 [2+] 
484.8 [2+] 
489.8 [2+] 
613.8 [2+] 
618.8 [2+] 
498.7 [2+] 
502.7 [2+] 
564.8 [2+] 
568.8 [2+] 
568.8 [2+] 
572.8 [2+] 
834.4 [2+] 
839.4 [2+] 
645.9 [2+] 
650.9 [2+] 
361.7 [2+] 
366.7 [2+] 
628.3 [2+] 
633.3 [2+] 
595.3 [y5] 
603.3 [y5] 
664.4 [y6] 
672.4 [y6] 
603.3 [y5] 
611.3 [y5] 
575.3 [y5] 
583.4 [y5] 
599.4 [y5] 
609.4 [y5] 
552.3 [y4] 
560.3 [y4] 
489.2 [y4] 
499.2 [y4] 
683.4 [y5] 
693.4 [y5] 
519.3 [y5] 
527.3 [y5] 
609.4 [y5] 
617.4 [y5] 
569.3 [y5] 
577.3 [y5] 
713.3 [y7]† 
723.3 [y7]† 
653.3 [y6] 
663.4 [y6] 
395.2 [y3] 
405.2 [y3] 
637.4 [y5] 
647.4 [y5] 
694.4 [y6] 
702.4 [y6] 
777.4 [y7] 
785.4 [y7] 
731.4 [y6] 
739.4 [y6] 
674.4 [y6] 
682.4 [y6] 
712.5 [y6] 
722.5 [y6] 
666.3 [y5] 
674.4 [y5] 
588.3 [y5] 
598.3 [y5] 
784.4 [y6] 
794.4 [y6] 
682.3 [y6] 
690.4 [y6] 
696.4 [y6] 
704.4 [y6] 
716.4 [y6] 
724.4 [y6] 
814.4 [y8] † 
824.4 [y8] † 
766.4 [y7] 
776.4 [y7] 
508.3 [y4] 
518.3 [y4] 
738.4 [y6] 
748.4 [y6] 
823.4 [y7] 
831.4 [y7] 
914.5 [y8] 
922.5 [y8] 
844.5 [y7] 
852.5 [y7] 
803.5 [y7] 
811.5 [y7] 
813.5 [y7] 
823.5 [y7] 
794.4 [y6] 
802.4 [y6] 
701.4 [y6] 
711.4 [y6] 
841.5 [y7] 
851.5 [y7] 
796.4 [y7] 
804.4 [y7] 
797.4 [y7] 
805.5 [y7] 
829.4 [y7] 
837.5 [y7] 
911.4 [y9] 
921.4 [y9] 
865.5 [y8] 
875.5 [y8] 
609.3 [y5] 
619.3 [y5] 
851.5 [y7] 
861.5 [y7] 
937.5 [y8] 
945.5 [y8] 
  
  
901.5 [y8] 
909.5 [y8] 
900.5 [y8] 
908.5 [y8] 
910.6 [y8] 
920.6 [y8] 
865.4 [y7] 
873.5 [y7] 
798.4 [y7] 
808.5 [y7] 
942.5 [y8] 
952.5 [y8] 
  
  
912.5 [y8] 
920.5 [y8] 
916.5 [y8] 
924.5 [y8] 
  
  
964.6 [y9] 
974.6 [y9] 
  
  
908.5 [y8] 
918.5 [y8] 
  
  
  
  
  
  
  
  
  
  
  
  
855.5 [y8] 
865.5 [y8] 
1013.6 [y9] 
1023.6 [y9] 
  
  
  
  
  
  
  
  
1078.6 [y10] 
1088.6 [y10] 
  
  
1005.6 [y9] 
1015.6 [y9] 
937.5 
945.5 
777.4 
785.5 
731.4 
739.4 
674.4 
682.4 
910.6 
920.6 
865.4 
873.5 
701.4 
711.4 
942.5 
952.5 
682.3 
690.4 
696.4 
704.4 
916.5 
924.5 
911.4 
921.4 
766.4 
776.4 
609.3 
619.3 
908.5 
918.5 
 
[K] = 13C615N4 labeled; [R] = 13C615N2 labelled; *oa-ToF MRM based acquisitions only; † <10% most abundant MRM fragment ion  
 Supplementary Table 2. Quantitative response, S/N and estimated LLOD of fifteen SIL peptides spiked into undepleted, tryptic digested 
human serum using tandem quadruple and oa-ToF mass spectrometry in combination with micro-fluidics (see section Experimental for 
details). The levels tested ranges from 62.5 amol to 12.5 fmol on-column. 
 
peptide sequence r2 S/N @ 125 amol on-column  estimated LLOD 
 MRM1 MRM2 oa-ToF1 oa-ToF2 MRM1 MRM2 oa-ToF1 oa-ToF2 MRM1 MRM2 oa-ToF1 oa-ToF2 
LVNEVTEFA[K] 
ATEHLSTLSE[K] 
TGLQEVEV[K] 
FPEVDVLT[K] 
FQPTLLTLP[R] 
TAAQNLYE[K] 
LGPLVEQG[R] 
AAAATGTIFTF[R] 
EANYIGSD[K] 
ESDTSYVSL[K] 
GYSIFSYAT[K] 
GFYFNKPTGYGSSS[R] 
LVNVVLGAHNV[R] 
ITLYG[R] 
SYPGLTSYLV[R] 
 
median 
0.9982 
0.9972 
0.9989 
0.9994 
0.9992 
0.9991 
0.9994 
0.9972 
0.9951 
0.9992 
0.9985 
0.9993 
0.9946 
0.9996 
0.9981 
- 
0.9977 
0.9964 
0.9960 
0.9955 
0.9989 
0.9957 
0.9987 
0.9995 
0.9934 
0.9949 
0.9912 
0.9864 
0.9966 
0.9968 
0.9983 
0.9930 
- 
0.9989 
0.9982 
0.9847 
0.9992 
0.9920 
0.9991 
0.9987 
0.9997 
0.9945 
0.9962 
0.9980 
0.9995 
0.9988 
0.9955 
0.9992 
0.9969 
0.9970 
0.9988 
0.9985 
0.9991 
0.9980 
0.9986 
0.9989 
0.9957 
0.9928 
0.9992 
0.9990 
8 
- 
5 
5 
13 
2 
14 
30 
5 
3 
10 
- 
2 
20 
6 
 
6 
- 
40 
20 
10 
26 
8 
37 
15 
10 
16 
17 
15 
4 
30 
20 
 
17 
40 
10 
- 
10 
100 
20 
50 
30 
6 
50 
20 
8 
3 
30 
8 
 
20 
20 
10 
20 
10 
30 
20 
20 
8 
4 
30 
40 
15 
- 
20 
15 
 
20 
40 
250 
60 
40 
25 
100 
20 
30 
50 
50 
30 
250 
125 
20 
50 
 
50 
- 
15 
15 
20 
20 
35 
10 
20 
20 
20 
10 
30 
125 
10 
30 
 
20 
5 
20 
- 
15 
3 
10 
5 
20 
25 
5 
15 
30 
100 
10 
30 
 
15 
15 
30 
15 
15 
20 
20 
20 
20 
50 
20 
10 
40 
150 
10 
20 
 
20 
 
r2 1/x weighting; peak-to-peak S/N; [K] = 13C615N4 labeled; [R] = 13C615N2 labeled; - = not calculated (isobaric interfering components or insufficient sensitivity) 
MRM1 = Xevo TQ-S micro tandem quadrupole; MRM2 = Xevo TQ-S tandem quadrupole; oa-ToF1 = Xevo G2-XS QTof hybrid oa-ToF; oa-ToF2 =Synapt G2-Si hybrid oa-ToF 
  
Supplementary Table 3. Determined plasma concentration of seven target peptides, representing six proteins, with %CV values using 
tandem quadruple and oa-ToF mass spectrometry in combination with micro-fluidics (see section Experimental for details). 
peptide sequence 
plasma concentration (n = 7) 
fmol/140 ng digested plasma 
%CV 
 MRM1 MRM2 oa-ToF1 oa-ToF2 MRM1 MRM2 oa-ToF1 oa-ToF2 
TGLQEVEVK 
FPEVDVLTK 
FQPTLLTLPR 
TAAQNLYEK 
LGPLVEQGR 
ESDTSYVSLK 
GYSIFSYATK 
2.78 
1.14 
0.12 
0.89 
0.39 
0.13 
0.061 
3.7 
1.16 
0.15 
1.05 
0.64 
0.12 
0.055 
3.1 
1.25 
0.11 
1.18 
0.44 
0.093 
0.026 
4.4 
1.19 
0.16 
1.39 
0.64 
0.099 
0.050 
7.7 
8.9 
7.1 
10.0 
10.1 
18.3 
10.2 
3.9 
7.6 
7.1 
4.7 
1.7 
10.0 
9.5 
8.5 
15.0 
19.7 
9.3 
8.9 
15.6 
23.8 
7.5 
9.9 
13.8 
9.5 
9.4 
10.9 
11.0 
 
MRM1 = Xevo TQ-S tandem quadrupole micro; MRM2 = Xevo TQ-S tandem quadrupole; oa-ToF1 = Xevo G2-XS QTof hybrid oa-ToF; oa-ToF2 =Synapt G2-Si hybrid oa-ToF 
 
Figure S1. Development of chromatographic conditions for LGPLVEQGR-13C615N4 (summed MRM transitions 489.784 > 499.25 + 489.784 > 
598.318 + 489.784 > 711.402 + 489.784 > 808.455 contrasting generic (A) and optimized (B) chromatographic conditions, temperature and 
gradient slope. The peak of interest is retention time (min) annotated. The '1', '2' and '3' components are isobaric species with one or more shared 
transitions. See section Experimental Conditions for final chromatographic conditions. 
Figure S2. LLOQ MRM chromatograms for 5 fg of sulfadimethoxine in absence of matrix injected on column. The left (A) pane illustrates the 
tandem quadrupole MRM chromatogram monitoring the m/z 311.1 > 156.1 transition using 0.7 FWHM quadrupole resolution settings and the right 
(B) pan the high resolution TOF MRM equivalent isolating m/z 311.1 with 0.7 FWHM quadrupole resolution and EDC TOF full scan MS/MS read 
out. The LLOQ was specified as the lowest concentration calibration point where the back calculated concentrations for all replicate injections were 
within 25% of the expected value. 
Figure S3. Example tandem quadrupole MRM chromatograms for ten SIL peptides injected 125 amol on-column using (A) 90 min reversed phase 
gradient nanoscale LC chromatography and (B) 45 min reversed phase gradient micro-fluidics. 
Figure S4. Calibration/quantitation curve for LGPLVEQGR-13C615N4 ranging from 15 amol to 1.5 nmol injected on-column using a 150 µm id 
precolumn based micro-fluidics column configuration in combination with tandem quadrupole (Xevo TQ-S) MRM, illustrating (A) linearity for the 
lower orders of the investigated range and (B) linear response of the LC-MS system across the complete dynamic range. See section 
Experimental Conditions and Supplementary Table 1 for additional experimental and MRM details. 
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Figure S5. Multivariate OPLS-DA analysis showing the separation and classification of HFPEF and HFREF samples. Circles = HFPEF patient 
samples; triangles = HFREF patient samples. The model indicates that disease can be partially classified using a multiplex tandem quadrupole 
LC-MRM-MS based assay. 
